Is REABS or MRK a better dividend investment in 2026?

REABS currently yields 85.11% with a 5% 5-year dividend growth rate. MRK yields 2.76% with 8.2% growth. The better choice depends on your goal: REABS offers higher current income.

What is the dividend yield difference between REABS and MRK?

REABS has a forward dividend yield of 85.11% ($2.00/share annually). MRK yields 2.76% ($3.32/share annually). The yield gap is 82.35 percentage points.

Home › Compare › REABS vs MRK

REABS vs MRK: Dividend Comparison 2026

REABS yields 85.11% · MRK yields 2.76%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 REABS wins by $2.02M in total portfolio value

INVESTMENT

TIME HORIZON10 years

REABS

● Live price

85.11%

Share price

$2.35

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$2.08M

Annual income

$627,483.66

Full REABS calculator →

MRK

Merck & Co. Inc.

● Live price

2.76%

Share price

$120.31

Annual div

$3.32

5Y div CAGR

32.7%

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$56.8K

Annual income

$9,798.13

Full MRK calculator →

Portfolio growth — REABS vs MRK

📍 REABS pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	REABS	MRK
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, REABS + MRK cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

REABS pays

MRK pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

REABS

Annual income on $10K today (after 15% tax)

$7,234.04/yr

After 10yr DRIP, annual income (after tax)

$533,361.11/yr

MRK

Annual income on $10K today (after 15% tax)

$234.56/yr

After 10yr DRIP, annual income (after tax)

$8,328.41/yr

At 15% tax rate, REABS beats the other by $525,032.70/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of REABS + MRK for your $10,000?

REABS: 50%MRK: 50%

100% MRK50/50100% REABS

Portfolio after 10yr

$1.07M

Annual income

$318,640.90/yr

Blended yield

29.85%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

REABS

No analyst data

MRK

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Price Target

$128.54

+6.8% upside vs current

Range: $100.00 — $150.00

Altman Z

4.0

Piotroski

6/9

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

REABS buys

MRK buys

No recent congressional trades found for REABS or MRK in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricREABSMRK

Forward yield	85.11% ✓	2.76%
Annual dividend / share	$2.00	$3.32 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	32.7% ✓
Portfolio after 10y	$2.08M	$56.8K ✓
Annual income after 10y	$627,483.66 ✓	$9,798.13
Total dividends collected	$1.82M	$28.9K ✓
Payment frequency	quarterly	quarterly
Sector	Stock	Healthcare

Year-by-year: REABS vs MRK ($10,000, DRIP)

Year	REABS Portfolio	REABS Income/yr	MRK Portfolio	MRK Income/yr	Gap
1← crossover	$19,211	$8,510.64	$11,206	$366.19	+$8.0K → REABS
2	$35,835	$15,279.89	$12,650	$502.35	+$23.2K → REABS
3	$64,982	$26,638.22	$14,407	$694.19	+$50.6K → REABS
4	$114,675	$45,144.37	$16,585	$967.82	+$98.1K → REABS
5	$197,158	$74,455.37	$19,342	$1,363.89	+$177.8K → REABS
6	$330,593	$119,634.65	$22,913	$1,947.19	+$307.7K → REABS
7	$541,214	$187,479.44	$27,662	$2,823.89	+$513.6K → REABS
8	$865,943	$286,843.50	$34,159	$4,173.35	+$831.8K → REABS
9	$1,355,484	$428,924.80	$43,337	$6,308.80	+$1.31M → REABS
10	$2,077,851	$627,483.66	$56,776	$9,798.13	+$2.02M → REABS

REABS vs MRK: Complete Analysis 2026

REABS — Stock

RSE Archive, LLC operates a platform for buying and selling equity shares in collectible assets. Its asset portfolio includes memorabilia, books and arts, cars, watches, luxury products, and wine and whisky. The company was incorporated in 2019 and is based in New York, New York.

Full REABS Calculator →

MRK — Healthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →

📬

Get this REABS vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

REABS vs SCHD REABS vs JEPI REABS vs O REABS vs KO REABS vs MAIN REABS vs JNJ REABS vs ABBV REABS vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.